Gene · 1663
NIH grants481
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1 to 20 of 481
| Grant | Title | DDX11 papers | Newest fiscal year |
|---|---|---|---|
| ZIAAG000741 | Roles Of DNA Helicases In Pathways Required For Maintenance Of Genomic Stability | 27 | 2025 |
| ZIAAG000753 | Fanconi Anemia Pathway | 25 | 2025 |
| ZIAAG000752 | Model Genetic Systems to Study DNA Repair | 19 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA016059 | Massey Cancer Center - Cancer Center Support Grant | 4 | 2025 |
| ZIAAI000713 | Replication mechanisms of human papillomaviruses (HPV) | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 3 | 2025 |
| R01AA028263 | Trans-omic Analysis of Alcohol Consumption and its Relation to Cardiovascular Disease | 3 | 2025 |
| R01CA142861 | Renewal: HPV and the DNA Damage Response | 3 | 2025 |
| ZIACP010190 | Genetic Epidemiology of Telomere Maintenance and Cancer Etiology | 3 | 2025 |
| P01CA100730 | Retrovirus Models of Cancer | 2 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 2 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 2 | 2025 |
| P30CA071789 | University of Hawaii Cancer Center CCSG | 2 | 2025 |
| R01AI160706 | Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy | 2 | 2025 |
| R01DE017336 | Epigenetic Regulation of Epstein-Barr Virus | 2 | 2025 |
| R01DE029471 | Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle | 2 | 2025 |
| R01GM051753 | Replication Fork Repair | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-13-0.2.1
Sources 13
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
- USPTO's sequence listingsPublic domain in the US. Source: United States Patent and Trademark Office, www.uspto.gov
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
- USPTO's sequence listingsUSPTO's sequence listings of patents and published applications, from its bulk data files. No license named for the files. USPTO's terms say "most government-produced materials appearing on this website are not subject to copyright restrictions within the United States and are therefore in the public domain", and ask that USPTO be given appropriate acknowledgement ("Source: United States Patent and Trademark Office, www.uspto.gov"). USPTO does not endorse ConductScience or this release. Read on 12 Nov 2026 at https://www.uspto.gov/terms-use-uspto-websites
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
Source: United States Patent and Trademark Office, www.uspto.gov. USPTO does not endorse ConductScience or this database.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1663/grants